Real-World Data on Early Initiation of Sodium-Glucose Co-Transporter-2 Inhibitors in Newly Diagnosed HFrEF
In this large multinational real-world data of patients with HFrEF, the prescription rate for SGLT2is within 6 weeks after the first HF hospitalization remained low. However, SGLT2i initiation was associated with improved outcomes, underscoring the importance of guideline-recommended early use.
Authors
- Gema Hernandez
- Guillaume Baudry (ORCID: https://orcid.org/0000-0002-9200-2729)
- Olivier Denquin
- Luca Monzo
- Nicolas Girerd
- Kevin Duarte
Institutions
- Custodix (Belgium) (BE)
- Tokyo Medical University Hospital (JP)
- Centre de Recherche en Automatique de Nancy (FR)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1093/eschf/xvag008
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00